CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Affinia Therapeutics receives FDA orphan drug designation for AFTX-201

RegulatoryAFTX-201Positive
AI Analysis

Summary

Affinia Therapeutics received FDA orphan drug designation for AFTX-201, a treatment candidate for BAG3-associated dilated cardiomyopathy (DCM).

Outcome Details

FDA orphan drug designation granted

Importance:5/10
Sentiment:
0.60
orphan drug designationcardiomyopathyBAG3rare disease

Read the original article

Published by Pharmaceutical Technology on July 23, 2026 9:39 AM

Read Original